Revenue Update on BioPharmX Corp(NYSEMKT:BPMX)

BioPharmX Corp(NYSEMKT:BPMX) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 23, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-0.08.

BioPharmX Corp (BPMX) shares turned negative on Fridays trading session with the shares closing down -0.0601 points or -10.93% at a volume of 8,89,502. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $0.55. The peak price level was also seen at $0.55 while the days lowest was $0.472. Finally the shares closed at $0.4899. The 52-week high of the shares is $1.5 while the 52-week low is $0.1883. According to the latest information available, the market cap of the company is $33 M.

Several Insider Transactions has been reported to the SEC. On Nov 29, 2016, Stephen Morlock (director) purchased 428,571 shares at $0.35 per share price.Also, On Aug 16, 2016, Resources Inc Franklin (10% owner) purchased 484,615 shares at $0.65 per share price.

BioPharmX Corporation is a specialty pharmaceutical company focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter or OTC products that address markets in women’s health and dermatology. The Company’s portfolio of product candidates includes two clinical stage product candidates: BPX01 a topical antibiotic for the treatment of acne and BPX03 a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition or FBC and cyclic mastalgia. The Company’s commercial product VI2OLET iodine is an OTC dietary supplement molecular iodine tablet that promotes breast health and is for the alleviation of benign breast pain associated with fibrocystic breast condition or FBC. The Company has one wholly owned subsidiary BioPharmX Inc.

Add Comment